Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. T...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. Elzéar Blvd. West, Laval, Canada

revoltingtrees Sep. 15 at 8:55 PM

$BHC Go prive for $25

0 · Reply

AKTN Sep. 15 at 7:01 PM

$BHC like a train wreck, you can't look away

0 · Reply

Coolhat1 Sep. 15 at 4:01 PM

$BHC THIS IS A GEM ITS ONE HEADLINE AWAY FROM 20 plus a share

0 · Reply

Bobberty Sep. 15 at 2:31 PM

$BHC and back to red. Was nice thinking I'd found a gem for a second there.

1 · Reply

Coolhat1 Sep. 14 at 8:23 PM

$BHC They were the ones who said, ‘We’re going to be out by Christmas.’ And Christmas would come, and Christmas would go. Then they’d say, ‘We’re going to be out by Easter.’ And Easter would come, and Easter would go. And then Thanksgiving, and then it would be Christmas again. And they died of a broken heart

0 · Reply

Coolhat1 Sep. 14 at 7:37 PM

$BHC 🗣️🗣️🗣️💯💯💯💯

0 · Reply

algomezus Sep. 14 at 7:27 PM

$BHC How is it that none of the big investors go and yell at management because it's bullshit they stole the company 5 years ago? How is it possible that no one is screaming bloody murder? 5 years of a failed spinoff. How is that possible? How can they steal a company like that? And not give a flying fuck

0 · Reply

FU2 Sep. 14 at 2:10 PM

$BHC $8

0 · Reply

FU2 Sep. 14 at 2:07 PM

$BHC what is the deal with the volume?

0 · Reply

Coolhat1 Sep. 13 at 1:47 AM

$BHC until it drop to 4s this stock STINKS

1 · Reply

Bausch Health and YUN expand to Mexico and additional EMEA Markets

Sep 8, 2026, 8:00 AM EDT - 8 days ago

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

2026-09-01T12:16:10.000Z - 15 days ago

Bausch Health announces availability of Solta Medical’s Fraxel FTX in Australia

Aug 27, 2026, 8:02 AM EDT - 20 days ago

Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

Aug 24, 2026, 4:30 PM EDT - 23 days ago

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Aug 17, 2026, 8:00 AM EDT - 4 weeks ago

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners

2026-08-16T12:49:43.000Z - 4 weeks ago

Bausch Health put volume heavy and directionally bearish

Aug 6, 2026, 7:04 AM EDT - 5 weeks ago

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

BLCO

Jul 29, 2026, 5:00 PM EDT - 7 weeks ago

Bausch Health Companies Earnings Call Transcript: Q2 2026

Jul 29, 2026, 5:00 PM EDT - 7 weeks ago

Bausch Health Companies Earnings release: Q2 2026

Jul 29, 2026, 5:00 PM EDT - 7 weeks ago

Bausch Health Companies Slides: Q2 2026

Jul 29, 2026, 5:00 PM EDT - 7 weeks ago

Bausch Health Companies Quarterly report: Q2 2026

2026-07-29T20:18:16.000Z - 7 weeks ago

Bausch Health reports Q2 non-GAAP EPS $1.26, consensus $1.01

Jul 29, 2026, 4:05 PM EDT - 7 weeks ago

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

Jul 9, 2026, 5:12 PM EDT - 2 months ago

Bausch to stop glaucoma eye drop development after trial miss

Jul 7, 2026, 7:00 AM EDT - 2 months ago

Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026

Jul 1, 2026, 4:15 PM EDT - 2 months ago

Michael Goettler Resigns from Bausch Health's Board of Directors

May 28, 2026, 4:15 PM EDT - 3 months ago

Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

May 20, 2026, 9:30 AM EDT - 3 months ago

Bausch Health Companies Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 4:15 PM EDT - 4 months ago

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

May 19, 2026, 10:25 AM EDT - 4 months ago

Bausch Health Companies Transcript: Barclays 30th Annual Leveraged Finance Conference 2026

May 19, 2026, 9:00 AM EDT - 4 months ago

Bausch Health Companies Transcript: AGM 2026

May 19, 2026, 7:00 AM EDT - 4 months ago

Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States

May 13, 2026, 7:00 AM EDT - 4 months ago

Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference

May 12, 2026, 4:15 PM EDT - 4 months ago

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

May 7, 2026, 7:00 AM EDT - 4 months ago

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

Apr 29, 2026, 5:00 PM EDT - 4 months ago

Bausch Health Companies Earnings Call Transcript: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 4 months ago

Bausch Health Companies Slides: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 4 months ago

Bausch Health Companies Earnings release: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 4 months ago

Bausch Health Companies Quarterly report: Q1 2026

2026-04-29T20:33:36.000Z - 4 months ago

Bausch Health reports Q1 non-GAAP EPS 78c, consensus 69c

2026-04-29T20:29:28.000Z - 4 months ago

Bausch Health sees 2026 revenue $10.67B-$10.92B, consensus $10.68B

Apr 29, 2026, 4:05 PM EDT - 4 months ago

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

Apr 23, 2026, 7:00 AM EDT - 4 months ago

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

Apr 14, 2026, 8:00 AM EDT - 5 months ago

Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering

Apr 8, 2026, 8:00 AM EDT - 5 months ago

Bausch Health Companies Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 5 months ago

Bausch Health Companies Proxy statement: Proxy filing

Apr 8, 2026, 7:00 AM EDT - 5 months ago

Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update

Apr 7, 2026, 7:00 AM EDT - 5 months ago

Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

2026-02-25T10:15:55.000Z - 6 months ago

Bausch Health price target lowered to $7 from $8 at Barclays

Feb 23, 2026, 8:00 AM EST - 6 months ago

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

Feb 19, 2026, 8:00 AM EST - 6 months ago

Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres

Feb 18, 2026, 5:00 PM EST - 7 months ago

Bausch Health Companies Earnings Call Transcript: Q4 2025

Feb 18, 2026, 5:00 PM EST - 7 months ago

Bausch Health Companies Annual report: Q4 2025

Feb 18, 2026, 5:00 PM EST - 7 months ago

Bausch Health Companies Earnings release: Q4 2025

Feb 18, 2026, 5:00 PM EST - 7 months ago

Bausch Health Companies Slides: Q4 2025

2026-02-18T21:21:45.000Z - 7 months ago

Bausch Health reports Q4 EPS (30c) vs. 25c a year ago

Feb 18, 2026, 4:05 PM EST - 7 months ago

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

Feb 17, 2026, 7:00 AM EST - 7 months ago

Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference

Feb 11, 2026, 8:00 AM EST - 7 months ago

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program

2026-02-02T19:40:25.000Z - 7 months ago

NY AG announces settlement with Lannett and Bausch Health

2026-01-23T18:55:29.000Z - 7 months ago

Bausch’s RED-C miss raises pressure ahead of Xifaxan LOE, Truist says

Jan 23, 2026, 7:52 AM EST - 7 months ago

Bausch Health's brain dysfunction treatment fails late-stage trial

Jan 23, 2026, 7:45 AM EST - 7 months ago

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

Jan 21, 2026, 7:00 AM EST - 7 months ago

Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026

Jan 14, 2026, 6:45 PM EST - 8 months ago

Bausch Health Companies Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 8 months ago

Bausch Health Companies Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 8 months ago

Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 5:35 PM EST - 8 months ago

Bausch Health Announces Final Results and Expiration of Exchange Offers

Dec 8, 2025, 7:22 PM EST - 9 months ago

Bausch Health Announces Early Exchange Offer Results for Exchange Offers

Dec 2, 2025, 10:50 AM EST - 9 months ago

Bausch Health Companies Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 7:00 AM EST - 9 months ago

Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China

Nov 24, 2025, 7:05 AM EST - 9 months ago

Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

Nov 18, 2025, 7:00 AM EST - 10 months ago

Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 8:18 AM EST - 10 months ago

Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical

Nov 13, 2025, 7:00 AM EST - 10 months ago

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

Nov 5, 2025, 8:00 AM EST - 10 months ago

Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease

Nov 3, 2025, 4:30 PM EST - 10 months ago

Bausch + Lomb to Hold Investor Day on Nov. 13

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Bausch Health Companies Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Bausch Health Companies Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Bausch Health Companies Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Bausch Health Companies Slides: Q3 2025

Oct 29, 2025, 4:05 PM EDT - 10 months ago

Bausch Health Announces Third Quarter 2025 Results

Oct 9, 2025, 7:00 AM EDT - 11 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

Sep 30, 2025, 8:00 AM EDT - 11 months ago

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Sep 30, 2025, 7:00 AM EDT - 11 months ago

Bausch Health to Announce Third Quarter 2025 Results on October 29

Sep 29, 2025, 8:00 AM EDT - 11 months ago

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Sep 11, 2025, 8:35 AM EDT - 1 year ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 7:00 AM EDT - 1 year ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 9, 2025, 7:00 AM EDT - 1 year ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 5, 2025, 8:02 AM EDT - 1 year ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Aug 27, 2025, 8:00 AM EDT - 1 year ago

Bausch Health Companies Proxy statement: Proxy Filing

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

revoltingtrees Sep. 15 at 8:55 PM

$BHC Go prive for $25

0 · Reply

AKTN Sep. 15 at 7:01 PM

$BHC like a train wreck, you can't look away

0 · Reply

Coolhat1 Sep. 15 at 4:01 PM

$BHC THIS IS A GEM ITS ONE HEADLINE AWAY FROM 20 plus a share

0 · Reply

Bobberty Sep. 15 at 2:31 PM

$BHC and back to red. Was nice thinking I'd found a gem for a second there.

1 · Reply

Coolhat1 Sep. 14 at 8:23 PM

0 · Reply

Coolhat1 Sep. 14 at 7:37 PM

$BHC 🗣️🗣️🗣️💯💯💯💯

0 · Reply

algomezus Sep. 14 at 7:27 PM

0 · Reply

FU2 Sep. 14 at 2:10 PM

$BHC $8

0 · Reply

FU2 Sep. 14 at 2:07 PM

$BHC what is the deal with the volume?

0 · Reply

Coolhat1 Sep. 13 at 1:47 AM

$BHC until it drop to 4s this stock STINKS

1 · Reply

bluedevil84 Sep. 12 at 3:44 PM

$BHC Buy in the high $5’s and sell in the high $6’s. Works every time (until it doesn’t LOL)

1 · Reply

algomezus Sep. 12 at 1:18 AM

$BHC if you don't hate this stock you're not a true long

1 · Reply

FU2 Sep. 11 at 9:05 PM

$BHC im the proud owner of more shares at $5.89.. didn't buy my full trading position because of its weakness, but ready to pull the trigger on more if it keeps dropping. This cycle for a year has been so predictable.

0 · Reply

Coolhat1 Sep. 11 at 6:57 PM

$BHC how is this going back and fourth 1 dollar or two ever month

0 · Reply

89quattro Sep. 11 at 11:58 AM

$BHC $BLCO St. Jude the Apostle is the patron saint of lost causes and impossible situations. At this point I doubt that even he could help this mess.

0 · Reply

FU2 Sep. 10 at 3:52 PM

$BHC got greedy, missed it this morning by .03. See if I get a second chance.

0 · Reply

Coolhat1 Sep. 10 at 2:42 PM

$BHC grabbed a couple at 5.95

0 · Reply

danielmaia12 Sep. 10 at 12:59 AM

$BHC 10$ next up

1 · Reply

FU2 Sep. 9 at 9:31 PM

$BHC $5.95 I load the boat again. Maybe 2 boats. 🤑

0 · Reply

GDS_investing Sep. 9 at 1:36 PM

$BHC when ?

0 · Reply

MarkeTimer Sep. 9 at 12:03 PM

$BHC Leerink Partners initiates coverage on BHC with Outperform Rating, $24 Price Target

2 · Reply

FU2 Sep. 8 at 12:35 PM

$BHC 2 news releases, the push to $8 started. MnM's doin theie game. Total inside manipulation. Love it

0 · Reply

Market Cap	2.12B
Revenue (ttm)	10.27B
Net Income (ttm)	157.00M
EPS (ttm)	N/A
PE Ratio	1.38
Forward PE	1.36
Profit Margin	1.53%
Debt to Equity Ratio	-25.86

Volume	1,565,800
Avg Vol	3,597,200
Day's Range	N/A - N/A
Shares Out	374.14M
Stochastic %K	4%
Beta	0.37
Analysts	Hold
Price Target	$7.42